Stirred Tank Bioreactor Market Size, Share & Analysis | 2032
Stirred Tank Bioreactor Market Size, Share & Analysis | 2032
Segments - by Type (Microbial Bioreactors/Fermenters, Cell Culture Bioreactors, Single-Use/Disposable Bioreactors, Bioreactors for Special Applications), by Capacity (Less than 10L, 11L-20 L, 21L-30L, More than 30L), by Application (Antibodies, Viral Vectors, Cell Therapies, Others), by End-user (Pharmaceutical and Biopharmaceutical Companies, Contract Development and Manufacturing Organizations (CDMOs))
Upcoming
| Report ID :HC-7208
| 4.8 Rating
| 88 Reviews
| 271 Pages
| Format :
Report Description
Market Outlook:
The Global Stirred Tank Bioreactor Market was estimated at USD 1,962.5 Million in 2023 and is anticipated to reach USD 4,148.0 Million by 2032, expanding at a CAGR of 8.9% during the forecast period.
A Stirred Tank Bioreactor (STR), also called a mixing tank bioreactor, is a closed vessel designed to provide a controlled environment for cultivating biological materials such as cells, microorganisms, or tissues. STR offers a medium that provides nutrients for cells to grow in and delivers sufficient mixing and aeration to the culture to encourage growth.
Macro-economic Factors
Rising GDPs of Emerging Economies
The GDP growth rate of a country, the overall economic growth, and the stability of a country significantly impact the market across the globe. High GDP growth rates lead to increased spending and investments in product development. Emerging economies such as Russia, India, China, the UAE, and other countries in Southeast Asia and Latin America are key destinations for various industries. According to the International Monetary Fund, the economic growth of emerging countries is growing by about 6% annually, whereas countries with an already well-established economy report growth rates below 3%. Countries with high GDP growth rates tend to have high expenditures. Thus, rising GDPs of emerging countries play a crucial role in fuelling the market.
R&D Activities
Research & development (R&D) plays a significant role in determining the growth and future advancements of a country or region. According to the National Science Foundation, the total global R&D spending in the biotechnology industry is registered at around USD 88.6 billion in 2021. R&D spending in the biotechnology industry doubled in the last five years, from 2018 to 2022. North America accounts for 59% of the global R&D spending, followed by Europe at 34%, and the Asia Pacific at 7% in 2022. R&D plays an enormous role from discovery to final approval and marketing, where regulatory bodies act as checkpoints. R&D has a major impact on the overall market.
Market Dynamics
Market Driver- Increasing Adoption of Bioreactor Systems in Industrial Applications
Bioreactor systems are revolutionizing various industries by providing a controlled environment for cultivating cells, and microorganisms. They act as miniature ecosystems, mimicking the ideal conditions for specific biological processes. In the bio-pharmaceutical industry, bioreactors are used in the large-scale production of vaccines, insulin, antibiotics, and other life-saving drugs. Bioreactors enable the controlled growth of cells producing vital medications. In biofuels and biomaterials industries, these systems are used to cultivate microorganisms that produce biofuels as a sustainable alternative to fossil fuels. They are also used to create bioplastics and other biomaterials that have reduced environmental impact.
In tissue engineering applications, bioreactors hold potential in regenerative medicine by culturing specific cells. In food production, bioreactor systems are used for the fermentation of food products such as yogurt and beer. They also offer possibilities for cultivating alternative protein sources such as cultured meat. Thus, the growing adoption of bioreactor systems is projected to drive the market in the coming years.
Market Driver- Expansion of Contract Manufacturing Organizations (CMOs)
Contract manufacturing organizations (CMOs) are specialized companies offering a range of services to pharmaceutical and biotechnology companies, including the development, manufacturing, and packaging of drugs and therapies. CMOs offer a cost-effective solution, as developing and maintaining in-house biomanufacturing capabilities are expensive. STRs help CMOs to scale production processes, from initial research to large-scale manufacturing, efficiently.
CMOs are expanding their global presence, particularly in regions with low manufacturing costs. This is expected to lead to the establishment of new CMO facilities, thus driving the demand for STRs. Thus, the expansion of CMOs is projected to drive the stirred tank bioreactors market in the coming years.
Market Restraint- Maintenance & Operational Costs
STRs are complex pieces of machinery with moving parts and sensitive components requiring regular maintenance and occasional repairs to ensure optimal performance. STRs require specialized facilities with controlled temperature, humidity, and air quality, which in turn, increases the operational costs. The ongoing costs accumulate, as bioprocessing necessitates a constant supply of consumables such as culture media, filters, and sterilization agents. Additionally, the cost of employing qualified personnel is significant, as operating and maintaining STRs requires skilled personnel with a deep understanding of bioprocessing principles and aseptic techniques.
Biopharmaceutical companies constantly seek ways to reduce production costs. High operational expenses associated with STRs prompt to exploration of alternative technologies. The high costs associated with STRs limit their adoption in developing countries thus, hindering the market.
Market Opportunity- Growing Research & Development
The healthcare industry is shifting toward personalized medicine that involves tailoring treatments to individual patients. This necessitates research & development (R&D) efforts to develop novel therapies such as gene editing and cell therapies, often relying on stirred tank bioreactors for efficient cell cultivation.
R&D efforts are directed toward developing new drugs and therapies, due to the growing emphasis on addressing unmet medical needs in areas such as cancer, neurodegenerative diseases, and rare genetic disorders. R&D activities are crucial for exploring advancements and translating them into tangible applications in areas such as gene editing and synthetic biology. Furthermore, the demand for STRs from research institutions, biotechnology companies, and academic labs is expected to rise significantly in the coming years. Thus, the growing research & development is projected to create new growth opportunities during the forecast period.
Scope of the Report
The report on the global stirred tank bioreactor market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes |
Details |
|
Report Title |
Stirred Tank Bioreactor Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast |
|
Base Year |
2023 |
|
Historic Data |
2017–2022 |
|
Forecast Period |
2024–2032 |
|
Segmentation |
By Type (Microbial Bioreactors/Fermenters, Cell Culture Bioreactors, Single-Use/Disposable Bioreactors, Bioreactors for Special Applications), By Capacity (Less than 10L, 11L-20 L, 21L-30L, more than 30L), By Application (Antibodies, Viral Vectors, Cell Therapies, Others), By End-user (Pharmaceutical and Biopharmaceutical Companies, Contract Development and Manufacturing Organizations (CDMOs)) |
|
Regional Scope |
Regions (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) |
|
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
|
Key Players Covered |
ABEC; Bailun Biotechnology Co.,Ltd; BRS Biotech OÜ; Danaher Corporation (Cytiva); Eppendorf SE; Esco VacciXcell; MDX Biotechnik International GmbH; Merck KGaA; Sartorius AG; Thermo Fisher Scientific Inc; and Other |
Segmental Outlook
On the based-on Type, the stirred tank bioreactor market is segmented into microbial bioreactors/fermenters, cell culture bioreactors, single-use/disposable bioreactors, and bioreactors for special applications.
The microbial bioreactors/fermenters segment is expected to hold a significant share of 28.8% during the forecast period, as it is a key method for producing enzymes used in various industries, such as food processing and biocatalysis.
Based on capacity, the stirred tank bioreactor market is segmented into less than 10L, 11L-20 L, 21L-30L, and more than 30L.
The less than 10L segment register a substantial share of the market in the coming years, as it is widely used in universities, research institutions, and biotechnology companies. An increase in investments in life sciences research fuels the demand for benchtop models.
On the basis of application, the stirred tank bioreactor market is segregated into antibodies, viral vectors, cell therapies, and others.
The antibodies segment is expected to hold a significant share of the market during the forecast period, as STRs are widely used for antibody-based therapeutics. Monoclonal antibodies are used to treat various diseases such as cancer, autoimmune disorders, and infectious diseases.
In terms of end-user, the stirred tank bioreactor market is fragmented into pharmaceutical and biopharmaceutical companies and contract development and manufacturing organizations (CDMOs).
The pharmaceutical and biopharmaceutical companies segment is expected to grow at a substantial CAGR during the forecast period, due to the rising demand of STRs in pharmaceutical and biopharmaceutical companies. Pharmaceutical companies are constantly investing in the R&D of novel biopharmaceuticals, leading to a need for STRs for pilot-scale production and clinical trials.
Regional Outlook
Based on regions, the market is separated into namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The market in North America is estimated to expand at a CAGR of 8.8% during the forecast period, owing to the presence of a well-established biopharmaceutical industry, strong academic research institutions, and government support for biotechnology. North America has a robust regulatory framework ensuring the quality and safety of biopharmaceuticals produced using STRs.
Europe accounted for a 30.7% share of the market in 2023, due to rising demand for biopharmaceuticals, including vaccines, monoclonal antibodies, and gene therapies. Increased collaboration between academic institutions, biopharmaceutical companies, and STR manufacturers also accelerates innovation and optimizes bioprocessing efficiency. The growth of Contract Development and Manufacturing Organizations (CDMOs) in Europe increases the need for advanced STR infrastructure.
Key Benefits for Industry Participants & Stakeholders
-
In-depth Analysis of the Global Stirred Tank Bioreactor Market
-
Historical, Current, and Projected Market Size in terms of Value
-
Potential & Niche Segments and Regions Exhibiting Promising Growth Covered
-
Industry Drivers, Restraints, and Opportunities Covered in the Study
-
Recent Industry Trends and Developments
-
Competitive Landscape & Strategies of Key Players
-
Neutral Perspective on Global Stirred Tank Bioreactor Market Performance
Segments
By Type
- Microbial Bioreactors/Fermenters
- Cell Culture Bioreactors
- Single-Use/Disposable Bioreactors
- Bioreactors for Special Applications
By Capacity
- Less than 10L
- 11L-20 L
- 21L-30L
- More than 30L
By Application
- Antibodies
- Viral Vectors
- Cell Therapies
- Others
By End-user
- Pharmaceutical and Biopharmaceutical Companies
- Contract Development and Manufacturing Organizations (CDMOs)
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Key Market Players Profiled in the Report
- ABEC
- Bailun Biotechnology Co.,Ltd
- BRS Biotech OÜ
- Danaher Corporation (Cytiva)
- Eppendorf SE
- Esco VacciXcell
- MDX Biotechnik International GmbH
- Merck KGaA
- Sartorius AG
- Thermo Fisher Scientific Inc
- Other
Competitive Landscape
-
Manufacturers operating in the global Stirred Tank Bioreactor market are ABEC; Bailun Biotechnology Co., Ltd; BRS Biotech OÜ; Danaher Corporation (Cytiva); Eppendorf SE; Esco VacciXcell; MDX Biotechnik International GmbH; Merck KGaA; Sartorius AG; Thermo Fisher Scientific Inc; and Other.
-
Market Players are pursuing key strategies such as collaborations, mergers & acquisitions, and geographic expansion where a potential opportunity arises for the global Stirred Tank Bioreactor market.
Frequently Asked Questions
Additional company profiles can be provided on request. For a discussion related to the above findings, click Speak to Analyst
Factors such as competitive strength and market positioning are key areas considered while selecting top companies to be profiled.
Increasing Adoption of Bioreactor Systems in Industrial Application, Expansion of Contract Manufacturing Organization (CMOs)are the factors expected to drive the market growth during the forecast period.
According to this Growth Market Reports report, the Global Stirred Tank Bioreactor Market is likely to register a CAGR of 8.9% during the forecast period 2024-2032, with a projected valuation of USD 4,148.0 million by the end of 2032.
Pharmaceutical and Biopharmaceutical Companies are the major end user of the global stirred tank bioreactor market.
Factors such as the rising GDP of emerging economies, governmental spending, and R&D activities are analyzed in the final report.
Major manufacturers include ABEC; Bailun Biotechnology Co., Ltd; BRS Biotech OÜ; Danaher Corporation (Cytiva); Eppendorf SE; Esco VacciXcell; MDX Biotechnik International GmbH; Merck KGaA; Sartorius AG; Thermo Fisher Scientific Inc; and Other.
The outbreak of Coronavirus disease in 2019 (COVID-19) hampered the global economy, created global interdependence, and challenged the governments of various nations. Numerous industries across the globe had significantly affected, due to the COVID-19 pandemic. The pandemic caused massive disruptions in supply chains, affecting the production and distribution of products.
In addition to market size (in US$ Million), Company Market Share (in % for the base year 2023), macroeconomic factors, and Market Dynamics.
The base year considered for the global stirred tank bioreactor market report is 2023. The complete analysis period is 2017 to 2032, wherein, 2017 to 2022 are the historic years, and the forecast is provided from 2023 to 2031.
Table Of Content
Chapter 1 Executive SummaryChapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Stirred Tank Bioreactor Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Stirred Tank Bioreactor Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Stirred Tank Bioreactor Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Stirred Tank Bioreactor Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Stirred Tank Bioreactor Market Size & Forecast, 2023-2032
4.5.1 Stirred Tank Bioreactor Market Size and Y-o-Y Growth
4.5.2 Stirred Tank Bioreactor Market Absolute $ Opportunity
Chapter 5 Global Stirred Tank Bioreactor Market Analysis and Forecast By Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities By Type
5.1.2 Basis Point Share (BPS) Analysis By Type
5.1.3 Absolute $ Opportunity Assessment By Type
5.2 Stirred Tank Bioreactor Market Size Forecast By Type
5.2.1 Microbial Bioreactors/Fermenters
5.2.2 Cell Culture Bioreactors
5.2.3 Single-Use/Disposable Bioreactors
5.2.4 Bioreactors for Special Applications
5.3 Market Attractiveness Analysis By Type
Chapter 6 Global Stirred Tank Bioreactor Market Analysis and Forecast By Capacity
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities By Capacity
6.1.2 Basis Point Share (BPS) Analysis By Capacity
6.1.3 Absolute $ Opportunity Assessment By Capacity
6.2 Stirred Tank Bioreactor Market Size Forecast By Capacity
6.2.1 Less than 10L
6.2.2 11L-20 L
6.2.3 21L-30L
6.2.4 More than 30L
6.3 Market Attractiveness Analysis By Capacity
Chapter 7 Global Stirred Tank Bioreactor Market Analysis and Forecast By Application
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities By Application
7.1.2 Basis Point Share (BPS) Analysis By Application
7.1.3 Absolute $ Opportunity Assessment By Application
7.2 Stirred Tank Bioreactor Market Size Forecast By Application
7.2.1 Antibodies
7.2.2 Viral Vectors
7.2.3 Cell Therapies
7.2.4 Others
7.3 Market Attractiveness Analysis By Application
Chapter 8 Global Stirred Tank Bioreactor Market Analysis and Forecast By End-user
8.1 Introduction
8.1.1 Key Market Trends & Growth Opportunities By End-user
8.1.2 Basis Point Share (BPS) Analysis By End-user
8.1.3 Absolute $ Opportunity Assessment By End-user
8.2 Stirred Tank Bioreactor Market Size Forecast By End-user
8.2.1 Pharmaceutical and Biopharmaceutical Companies
8.2.2 Contract Development and Manufacturing Organizations (CDMOs)
8.3 Market Attractiveness Analysis By End-user
Chapter 9 Global Stirred Tank Bioreactor Market Analysis and Forecast by Region
9.1 Introduction
9.1.1 Key Market Trends & Growth Opportunities By Region
9.1.2 Basis Point Share (BPS) Analysis By Region
9.1.3 Absolute $ Opportunity Assessment By Region
9.2 Stirred Tank Bioreactor Market Size Forecast By Region
9.2.1 North America
9.2.2 Europe
9.2.3 Asia Pacific
9.2.4 Latin America
9.2.5 Middle East & Africa (MEA)
9.3 Market Attractiveness Analysis By Region
Chapter 10 Coronavirus Disease (COVID-19) Impact
10.1 Introduction
10.2 Current & Future Impact Analysis
10.3 Economic Impact Analysis
10.4 Government Policies
10.5 Investment Scenario
Chapter 11 North America Stirred Tank Bioreactor Analysis and Forecast
11.1 Introduction
11.2 North America Stirred Tank Bioreactor Market Size Forecast by Country
11.2.1 U.S.
11.2.2 Canada
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 North America Stirred Tank Bioreactor Market Size Forecast By Type
11.6.1 Microbial Bioreactors/Fermenters
11.6.2 Cell Culture Bioreactors
11.6.3 Single-Use/Disposable Bioreactors
11.6.4 Bioreactors for Special Applications
11.7 Basis Point Share (BPS) Analysis By Type
11.8 Absolute $ Opportunity Assessment By Type
11.9 Market Attractiveness Analysis By Type
11.10 North America Stirred Tank Bioreactor Market Size Forecast By Capacity
11.10.1 Less than 10L
11.10.2 11L-20 L
11.10.3 21L-30L
11.10.4 More than 30L
11.11 Basis Point Share (BPS) Analysis By Capacity
11.12 Absolute $ Opportunity Assessment By Capacity
11.13 Market Attractiveness Analysis By Capacity
11.14 North America Stirred Tank Bioreactor Market Size Forecast By Application
11.14.1 Antibodies
11.14.2 Viral Vectors
11.14.3 Cell Therapies
11.14.4 Others
11.15 Basis Point Share (BPS) Analysis By Application
11.16 Absolute $ Opportunity Assessment By Application
11.17 Market Attractiveness Analysis By Application
11.18 North America Stirred Tank Bioreactor Market Size Forecast By End-user
11.18.1 Pharmaceutical and Biopharmaceutical Companies
11.18.2 Contract Development and Manufacturing Organizations (CDMOs)
11.19 Basis Point Share (BPS) Analysis By End-user
11.20 Absolute $ Opportunity Assessment By End-user
11.21 Market Attractiveness Analysis By End-user
Chapter 12 Europe Stirred Tank Bioreactor Analysis and Forecast
12.1 Introduction
12.2 Europe Stirred Tank Bioreactor Market Size Forecast by Country
12.2.1 Germany
12.2.2 France
12.2.3 Italy
12.2.4 U.K.
12.2.5 Spain
12.2.6 Russia
12.2.7 Rest of Europe
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Europe Stirred Tank Bioreactor Market Size Forecast By Type
12.6.1 Microbial Bioreactors/Fermenters
12.6.2 Cell Culture Bioreactors
12.6.3 Single-Use/Disposable Bioreactors
12.6.4 Bioreactors for Special Applications
12.7 Basis Point Share (BPS) Analysis By Type
12.8 Absolute $ Opportunity Assessment By Type
12.9 Market Attractiveness Analysis By Type
12.10 Europe Stirred Tank Bioreactor Market Size Forecast By Capacity
12.10.1 Less than 10L
12.10.2 11L-20 L
12.10.3 21L-30L
12.10.4 More than 30L
12.11 Basis Point Share (BPS) Analysis By Capacity
12.12 Absolute $ Opportunity Assessment By Capacity
12.13 Market Attractiveness Analysis By Capacity
12.14 Europe Stirred Tank Bioreactor Market Size Forecast By Application
12.14.1 Antibodies
12.14.2 Viral Vectors
12.14.3 Cell Therapies
12.14.4 Others
12.15 Basis Point Share (BPS) Analysis By Application
12.16 Absolute $ Opportunity Assessment By Application
12.17 Market Attractiveness Analysis By Application
12.18 Europe Stirred Tank Bioreactor Market Size Forecast By End-user
12.18.1 Pharmaceutical and Biopharmaceutical Companies
12.18.2 Contract Development and Manufacturing Organizations (CDMOs)
12.19 Basis Point Share (BPS) Analysis By End-user
12.20 Absolute $ Opportunity Assessment By End-user
12.21 Market Attractiveness Analysis By End-user
Chapter 13 Asia Pacific Stirred Tank Bioreactor Analysis and Forecast
13.1 Introduction
13.2 Asia Pacific Stirred Tank Bioreactor Market Size Forecast by Country
13.2.1 China
13.2.2 Japan
13.2.3 South Korea
13.2.4 India
13.2.5 Australia
13.2.6 South East Asia (SEA)
13.2.7 Rest of Asia Pacific (APAC)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Asia Pacific Stirred Tank Bioreactor Market Size Forecast By Type
13.6.1 Microbial Bioreactors/Fermenters
13.6.2 Cell Culture Bioreactors
13.6.3 Single-Use/Disposable Bioreactors
13.6.4 Bioreactors for Special Applications
13.7 Basis Point Share (BPS) Analysis By Type
13.8 Absolute $ Opportunity Assessment By Type
13.9 Market Attractiveness Analysis By Type
13.10 Asia Pacific Stirred Tank Bioreactor Market Size Forecast By Capacity
13.10.1 Less than 10L
13.10.2 11L-20 L
13.10.3 21L-30L
13.10.4 More than 30L
13.11 Basis Point Share (BPS) Analysis By Capacity
13.12 Absolute $ Opportunity Assessment By Capacity
13.13 Market Attractiveness Analysis By Capacity
13.14 Asia Pacific Stirred Tank Bioreactor Market Size Forecast By Application
13.14.1 Antibodies
13.14.2 Viral Vectors
13.14.3 Cell Therapies
13.14.4 Others
13.15 Basis Point Share (BPS) Analysis By Application
13.16 Absolute $ Opportunity Assessment By Application
13.17 Market Attractiveness Analysis By Application
13.18 Asia Pacific Stirred Tank Bioreactor Market Size Forecast By End-user
13.18.1 Pharmaceutical and Biopharmaceutical Companies
13.18.2 Contract Development and Manufacturing Organizations (CDMOs)
13.19 Basis Point Share (BPS) Analysis By End-user
13.20 Absolute $ Opportunity Assessment By End-user
13.21 Market Attractiveness Analysis By End-user
Chapter 14 Latin America Stirred Tank Bioreactor Analysis and Forecast
14.1 Introduction
14.2 Latin America Stirred Tank Bioreactor Market Size Forecast by Country
14.2.1 Brazil
14.2.2 Mexico
14.2.3 Rest of Latin America (LATAM)
14.3 Basis Point Share (BPS) Analysis by Country
14.4 Absolute $ Opportunity Assessment by Country
14.5 Market Attractiveness Analysis by Country
14.6 Latin America Stirred Tank Bioreactor Market Size Forecast By Type
14.6.1 Microbial Bioreactors/Fermenters
14.6.2 Cell Culture Bioreactors
14.6.3 Single-Use/Disposable Bioreactors
14.6.4 Bioreactors for Special Applications
14.7 Basis Point Share (BPS) Analysis By Type
14.8 Absolute $ Opportunity Assessment By Type
14.9 Market Attractiveness Analysis By Type
14.10 Latin America Stirred Tank Bioreactor Market Size Forecast By Capacity
14.10.1 Less than 10L
14.10.2 11L-20 L
14.10.3 21L-30L
14.10.4 More than 30L
14.11 Basis Point Share (BPS) Analysis By Capacity
14.12 Absolute $ Opportunity Assessment By Capacity
14.13 Market Attractiveness Analysis By Capacity
14.14 Latin America Stirred Tank Bioreactor Market Size Forecast By Application
14.14.1 Antibodies
14.14.2 Viral Vectors
14.14.3 Cell Therapies
14.14.4 Others
14.15 Basis Point Share (BPS) Analysis By Application
14.16 Absolute $ Opportunity Assessment By Application
14.17 Market Attractiveness Analysis By Application
14.18 Latin America Stirred Tank Bioreactor Market Size Forecast By End-user
14.18.1 Pharmaceutical and Biopharmaceutical Companies
14.18.2 Contract Development and Manufacturing Organizations (CDMOs)
14.19 Basis Point Share (BPS) Analysis By End-user
14.20 Absolute $ Opportunity Assessment By End-user
14.21 Market Attractiveness Analysis By End-user
Chapter 15 Middle East & Africa (MEA) Stirred Tank Bioreactor Analysis and Forecast
15.1 Introduction
15.2 Middle East & Africa (MEA) Stirred Tank Bioreactor Market Size Forecast by Country
15.2.1 Saudi Arabia
15.2.2 South Africa
15.2.3 UAE
15.2.4 Rest of Middle East & Africa (MEA)
15.3 Basis Point Share (BPS) Analysis by Country
15.4 Absolute $ Opportunity Assessment by Country
15.5 Market Attractiveness Analysis by Country
15.6 Middle East & Africa (MEA) Stirred Tank Bioreactor Market Size Forecast By Type
15.6.1 Microbial Bioreactors/Fermenters
15.6.2 Cell Culture Bioreactors
15.6.3 Single-Use/Disposable Bioreactors
15.6.4 Bioreactors for Special Applications
15.7 Basis Point Share (BPS) Analysis By Type
15.8 Absolute $ Opportunity Assessment By Type
15.9 Market Attractiveness Analysis By Type
15.10 Middle East & Africa (MEA) Stirred Tank Bioreactor Market Size Forecast By Capacity
15.10.1 Less than 10L
15.10.2 11L-20 L
15.10.3 21L-30L
15.10.4 More than 30L
15.11 Basis Point Share (BPS) Analysis By Capacity
15.12 Absolute $ Opportunity Assessment By Capacity
15.13 Market Attractiveness Analysis By Capacity
15.14 Middle East & Africa (MEA) Stirred Tank Bioreactor Market Size Forecast By Application
15.14.1 Antibodies
15.14.2 Viral Vectors
15.14.3 Cell Therapies
15.14.4 Others
15.15 Basis Point Share (BPS) Analysis By Application
15.16 Absolute $ Opportunity Assessment By Application
15.17 Market Attractiveness Analysis By Application
15.18 Middle East & Africa (MEA) Stirred Tank Bioreactor Market Size Forecast By End-user
15.18.1 Pharmaceutical and Biopharmaceutical Companies
15.18.2 Contract Development and Manufacturing Organizations (CDMOs)
15.19 Basis Point Share (BPS) Analysis By End-user
15.20 Absolute $ Opportunity Assessment By End-user
15.21 Market Attractiveness Analysis By End-user
Chapter 16 Competition Landscape
16.1 Stirred Tank Bioreactor Market: Competitive Dashboard
16.2 Global Stirred Tank Bioreactor Market: Market Share Analysis, 2023
16.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
16.3.1 ABEC
16.3.2 Bailun Biotechnology Co.,Ltd
16.3.3 BRS Biotech OÜ
16.3.4 Danaher Corporation (Cytiva)
16.3.5 Eppendorf SE
16.3.6 Esco VacciXcell
16.3.7 MDX Biotechnik International GmbH
16.3.8 Merck KGaA
16.3.9 Sartorius AG
16.3.10 Thermo Fisher Scientific Inc
16.3.11 Other
Methodology
Related Reports
Some other reports from this category!
Our Clients
